Similar to the results obtained on tumors from POLE/POLD1 variant carriers by Mur et al. [9], MMR deficiency-associated mutational signatures substantially contributed to the mutational signature spectrum in 5 of 14 (36%) gliomas analyzed here. This evidence concerns the gene POLD1 and central nervous system cancer.